Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05731908 · ClinicalTrials.gov registry record · Phase 1
A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05731908 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 28 participants.
The verdict
NCT05731908, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The main objective of this trial is to assess the effect of mild and moderate hepatic impairment (Child-Pugh classification A and B) on the pharmacokinetics, safety, and tolerability of BI 690517 in comparison with a control group with normal hepatic function.
Interventions
- DRUG BI 690517
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2023-04-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05731908
The ClinicalTrials.gov registry entry for NCT05731908 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BI 690517 is the first listed.
NCT05731908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05731908 about?
NCT05731908 is a clinical study titled "A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems". The main objective of this trial is to assess the effect of mild and moderate hepatic impairment (Child-Pugh classification A and B) on the pharmacokinetics, safety, and tolerability of BI 690517 in comparison with a control group with normal hepatic function.
What is the current status of trial NCT05731908?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-02-21. Estimated completion is 2023-04-13.
What interventions are being tested in trial NCT05731908?
The interventions under investigation include: BI 690517 (DRUG).
Who is sponsoring clinical trial NCT05731908?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.